These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 9868652)
1. Randomized trial of lipid-based amphotericin B for invasive aspergillosis in neutropenic hosts is an important step forward. Karp JE; Merz WG Clin Infect Dis; 1998 Dec; 27(6):1413-4. PubMed ID: 9868652 [No Abstract] [Full Text] [Related]
2. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443 [TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Cordonnier C; Bresnik M; Ebrahimi R Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618 [TBL] [Abstract][Full Text] [Related]
4. Case reports. Invasive pulmonary aspergillosis in non-neutropenic patients treated with liposomal amphotericin B. Zhirong Y; Wanqing L; Weihua P Mycoses; 1999; 42(11-12):679-82. PubMed ID: 10680448 [TBL] [Abstract][Full Text] [Related]
5. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Dornbusch HJ; Urban CE; Pinter H; Ginter G; Fotter R; Becker H; Miorini T; Berghold C Pediatr Hematol Oncol; 1995; 12(6):577-86. PubMed ID: 8589003 [TBL] [Abstract][Full Text] [Related]
6. Fungal infection and fever of unknown origin in neutropenic patients. Bodey GP Am J Med; 1986 May; 80(5C):112-9. PubMed ID: 3717185 [No Abstract] [Full Text] [Related]
7. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Ellis M; Spence D; de Pauw B; Meunier F; Marinus A; Collette L; Sylvester R; Meis J; Boogaerts M; Selleslag D; Krcmery V; von Sinner W; MacDonald P; Doyen C; Vandercam B Clin Infect Dis; 1998 Dec; 27(6):1406-12. PubMed ID: 9868651 [TBL] [Abstract][Full Text] [Related]
8. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R; Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860 [TBL] [Abstract][Full Text] [Related]
9. Voriconazole versus amphotericin B in cancer patients with neutropenia. Jørgensen KJ; Gøtzsche PC; Johansen HK Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492 [TBL] [Abstract][Full Text] [Related]
10. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Behre GF; Schwartz S; Lenz K; Ludwig WD; Wandt H; Schilling E; Heinemann V; Link H; Trittin A; Boenisch O Ann Hematol; 1995 Dec; 71(6):287-91. PubMed ID: 8534760 [TBL] [Abstract][Full Text] [Related]
12. Invasive cerebral aspergillosis in a patient with aplastic anemia. Response to liposomal amphotericin and surgery. Rodríguez DL; López CA; Cobos EB; Blanco AJ; Fernández AF; Araujo LF Haematologica; 1999 Aug; 84(8):758-9. PubMed ID: 10457420 [No Abstract] [Full Text] [Related]
13. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Clemons KV; Stevens DA Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807 [TBL] [Abstract][Full Text] [Related]
14. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. Sims-McCallum RP Am J Health Syst Pharm; 2003 Nov; 60(22):2352-6. PubMed ID: 14652986 [No Abstract] [Full Text] [Related]
15. Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults. Anaissie EJ Clin Infect Dis; 2007 May; 44(10):1298-306. PubMed ID: 17443466 [No Abstract] [Full Text] [Related]
16. Successful treatment of an invasive aspergillosis of the skull base and paranasal sinuses with liposomal amphotericin B and itraconazole. Streppel M; Bachmann G; Arnold G; Damm M; Stennert E Ann Otol Rhinol Laryngol; 1999 Feb; 108(2):205-7. PubMed ID: 10030242 [TBL] [Abstract][Full Text] [Related]
17. Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery. Iemmolo RM; Rossanese A; Rotilio A; Mattisi G; Gerunda GE; Merenda R; Neri D; Crepaldi G; Strazzabosco M J Hepatol; 1998 Mar; 28(3):518-22. PubMed ID: 9551693 [TBL] [Abstract][Full Text] [Related]
18. [Progress in combination therapy for invasive aspergillosis]. Luo L; Tong Z Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jan; 37(1):41-4. PubMed ID: 24694973 [No Abstract] [Full Text] [Related]
19. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720 [TBL] [Abstract][Full Text] [Related]
20. Isolated cerebral aspergillosis without a portal of entry--complete recovery after liposomal amphotericin B and surgical treatment. García A; Mazuecos A; Clayo A; Pérez-Requena J; Mangas A; Alonso F; Ceballos M; Rivero M Nephrol Dial Transplant; 1998 Sep; 13(9):2385-7. PubMed ID: 9761532 [No Abstract] [Full Text] [Related] [Next] [New Search]